Zacks Research upgraded shares of Terumo (OTCMKTS:TRUMY – Free Report) to a hold rating in a research report released on Thursday,Zacks.com reports.
Separately, Nomura upgraded shares of Terumo to a “hold” rating in a research note on Tuesday, February 24th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Get Our Latest Stock Report on TRUMY
Terumo Stock Down 1.8%
Terumo (OTCMKTS:TRUMY – Get Free Report) last announced its quarterly earnings results on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The business had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.82 billion. Terumo had a return on equity of 9.01% and a net margin of 11.74%.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Further Reading
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
